Background: In January 2020, the US FDA published two final guidelines, one entitled "In vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry" and the other entitled "Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry". These were updated from the 2017 draft in vitro and clinical DDI guidance.
Methods: This study is aimed to provide an analysis of the updates along with a comparison of the DDI guidelines published by the European Medicines Agency (EMA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) along with the current literature.
Results: The updates were provided in the final FDA DDI guidelines and explained the rationale of those changes based on the understanding from research and literature. Furthermore, a comparison among the FDA, EMA, and PMDA DDI guidelines are presented in Tables 1, 2 and 3.
Conclusion: The new 2020 clinical DDI guidance from the FDA now has even higher harmonization with the guidance (or guidelines) from the EMA and PMDA. A comparison of DDI guidance from the FDA 2017, 2020, EMA, and PMDA on CYP and transporter based DDI, mathematical models, PBPK, and clinical evaluation of DDI is presented in this review.
Keywords: CYP; Cytochrome P450; DDI; PBPK; PK interaction; clinical DDI risk; in vitro assay; transporter.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Kosugi Y, Hirabayashi H, Igari T, Fujioka Y, Hara Y, Okuda T, Moriwaki T. Kosugi Y, et al. Xenobiotica. 2012 Feb;42(2):127-38. doi: 10.3109/00498254.2011.626087. Epub 2011 Nov 5. Xenobiotica. 2012. PMID: 22117526
Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, Lim HK, MacLauchlin C, Prakash C, Surapaneni S, Tse S, Upthagrove A, Walsky RL, Wen B, Zeng Z. Yu H, et al. Drug Metab Dispos. 2015 Apr;43(4):620-30. doi: 10.1124/dmd.114.059345. Epub 2015 Feb 5. Drug Metab Dispos. 2015. PMID: 25655830
Iwatsubo T. Iwatsubo T. Drug Metab Pharmacokinet. 2020 Feb;35(1):71-75. doi: 10.1016/j.dmpk.2019.10.006. Epub 2019 Oct 22. Drug Metab Pharmacokinet. 2020. PMID: 31757749 Review.
Yang X, Fan J, Zhang L. Yang X, et al. Methods Mol Biol. 2021;2342:595-629. doi: 10.1007/978-1-0716-1554-6_19. Methods Mol Biol. 2021. PMID: 34272707
Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara KI, Snoeys J, Nakakariya M, Chu X, Beneton M, Chen Y, Huth F, Narayanan R, Mukherjee D, Dixit V, Sugiyama Y, Neuhoff S. Taskar KS, et al. Clin Pharmacol Ther. 2020 May;107(5):1082-1115. doi: 10.1002/cpt.1693. Epub 2019 Dec 31. Clin Pharmacol Ther. 2020. PMID: 31628859 Free PMC article. Review.
Kaehler M, von Bubnoff N, Cascorbi I, Gorantla SP. Kaehler M, et al. Front Pharmacol. 2024 Jul 22;15:1422565. doi: 10.3389/fphar.2024.1422565. eCollection 2024. Front Pharmacol. 2024. PMID: 39104388 Free PMC article. Review.
Fardel O, Moreau A, Carteret J, Denizot C, Le Vée M, Parmentier Y. Fardel O, et al. Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):527-539. doi: 10.1007/s13318-024-00902-7. Epub 2024 Jul 3. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38958896 Review.
Kulkarni CP, Yang J, Koleske ML, Lara G, Alam K, Raw A, Rege B, Zhao L, Lu D, Zhang L, Yu LX, Lionberger RA, Giacomini KM, Kroetz DL, Yee SW. Kulkarni CP, et al. Pharmaceutics. 2024 May 10;16(5):647. doi: 10.3390/pharmaceutics16050647. Pharmaceutics. 2024. PMID: 38794309 Free PMC article.
Li T, Zhou S, Wang L, Zhao T, Wang J, Shao F. Li T, et al. J Pharmacokinet Pharmacodyn. 2024 Aug;51(4):367-384. doi: 10.1007/s10928-024-09912-z. Epub 2024 Mar 30. J Pharmacokinet Pharmacodyn. 2024. PMID: 38554227
Lee JM, Yoon JH, Maeng HJ, Kim YC. Lee JM, et al. Pharmaceutics. 2024 Feb 16;16(2):280. doi: 10.3390/pharmaceutics16020280. Pharmaceutics. 2024. PMID: 38399334 Free PMC article.